Projects funded by the NCN

GPR18 orphan receptor. Search for the tools to investigate GPR18 as potential therapeutic target

Call: OPUS 6 , Panel: NZ7

Principal investigator: prof. Katarzyna Justyna Kieć-Kononowicz

Uniwersytet Jagielloński- Collegium Medicum, Collegium Medicum; Wydział Farmaceutyczny

Inhibition of p21-Activated Kinase (PAK) as a new molecular target in the treatment of chronic myeloid leukemia (CML)

Call: OPUS 6 , Panel: NZ7

Principal investigator: dr hab. Sylwia Flis

Narodowy Instytut Leków

Transcription factor MeCP2 as an intracellular object of study on the mechanism of depression and as a potential pharmac...

Call: SONATA 5 , Panel: NZ7

Principal investigator: dr Magdalena Jolanta Sowa-Kućma

Instytut Farmakologii PAN

Evaluation of peroxiredoxins 1 and 2 along with the thioredoxin-thioredoxin reductase system as new therapeutic targets ...

Call: OPUS 4 , Panel: NZ7

Principal investigator: dr hab. Radosław Zagożdżon

Warszawski Uniwersytet Medyczny, I Wydział Lekarski

DNA double-stranded break repair proteins as a target for personalized cancer therapy based on synthetic lethality

Call: OPUS 4 , Panel: NZ7

Principal investigator: dr hab. Tomasz Śliwiński

Uniwersytet Łódzki, Wydział Biologii i Ochrony Środowiska

PHARMACOTHERAPY OF OSTEOARTHRITIS: TRPV1 AND CB1 RECEPTORS AND THEIR ENDOGENOUS LIGANDS AS NEW TARGETS FOR PHARMACOLOGIC...

Call: SONATA BIS 2 , Panel: NZ7

Principal investigator: dr hab. Katarzyna Maria Starowicz-Bubak

Instytut Farmakologii PAN

The group III metabotropic glutamate receptors as a target for future antypsychotic drugs

Call: MAESTRO 3 , Panel: NZ7

Principal investigator: prof. Andrzej Pilc

Instytut Farmakologii PAN